NASDAQ · PETS
Healthcare · Medical - Pharmaceuticals
$1.32
Down-$0.01 (-0.38%)
Updated Oct 6, 2026, 7:49 PM
SID Score
2.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PETS
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
PETS closed at $1.32 after 20 trading sessions, down 25.00% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $1.35 | $1.35 | $1.31 | $1.32 | 66.89K |
| Oct 2, 2026 | $1.36 | $1.37 | $1.33 | $1.36 | 185.19K |
| Oct 1, 2026 | $1.38 | $1.39 | $1.37 | $1.37 | 55.27K |
| Sep 30, 2026 | $1.38 | $1.42 | $1.3616 | $1.38 | 85.84K |
| Sep 29, 2026 | $1.42 | $1.42 | $1.375 | $1.40 | 73.67K |
| Sep 28, 2026 | $1.53 | $1.53 | $1.40 | $1.405 | 275.23K |
| Sep 25, 2026 | $1.55 | $1.56 | $1.53 | $1.53 | 224.71K |
| Sep 24, 2026 | $1.55 | $1.57 | $1.55 | $1.555 | 83.67K |
| Sep 23, 2026 | $1.57 | $1.57 | $1.55 | $1.55 | 95.6K |
| Sep 22, 2026 | $1.61 | $1.61 | $1.57 | $1.57 | 117.82K |
| Sep 21, 2026 | $1.72 | $1.7292 | $1.60 | $1.60 | 316.66K |
| Sep 18, 2026 | $1.60 | $1.62 | $1.58 | $1.61 | 254.31K |
| Sep 17, 2026 | $1.61 | $1.625 | $1.575 | $1.62 | 219.83K |
| Sep 16, 2026 | $1.63 | $1.63 | $1.60 | $1.60 | 75.5K |
| Sep 15, 2026 | $1.68 | $1.68 | $1.61 | $1.62 | 123.98K |
| Sep 14, 2026 | $1.65 | $1.69 | $1.65 | $1.67 | 93.59K |
| Sep 11, 2026 | $1.71 | $1.7499 | $1.65 | $1.65 | 37.09K |
| Sep 10, 2026 | $1.70 | $1.745 | $1.675 | $1.70 | 138.35K |
| Sep 9, 2026 | $1.73 | $1.75 | $1.71 | $1.71 | 67.01K |
| Sep 8, 2026 | $1.81 | $1.81 | $1.74 | $1.76 | 64.17K |
The latest Smart Investors Daily articles mentioning PETS.
Company
Market Activity
Research & News
PETS research
Company profile and research snapshot.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 25, 2026 | Morgan Stanley | Underweight | — |
| Apr 17, 2025 | Morgan Stanley | Underweight | — |
| Aug 7, 2024 | Lake Street | Hold | — |
| Jun 12, 2024 | Lake Street | Buy | — |
| Jun 12, 2024 | Morgan Stanley | Underweight | — |
No generated briefing is available yet.
prnewswire.com · Dec 11, 2025
NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. ("PetMed" or the "Company") (NASDAQ: PETS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PETS.
